21
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      A glimpse into the eye of the COVID-19 cytokine storm

      discussion
      a , b , c , *
      EBioMedicine
      The Authors. Published by Elsevier B.V.

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The pathogenesis of pandemic coronavirus disease-2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) likely depends heavily on disruption of immune and inflammatory processes. Thus far, the precise immune mechanisms have not been fully elucidated or studied in detail. In this issue of EBioMedicine, Liu and colleagues [1] showed that patients with severe COVID-19 had lymphopenia and increased neutrophil counts along with high levels of circulating pro-inflammatory cytokines compared to patients with mild COVID-19 illness. The investigators used flow cytometry to investigate immune phenotype and function of peripheral blood mononuclear cells (PBMC), as well as quantified plasma cytokine levels, from 40 COVID-19 patients. In particular, substantial depletion of CD8+ T cells were associated with disease severity, and both the ratios of neutrophils to CD8+ T cells (N8R) and neutrophils to lymphocytes (NLR) were predictive of COVID-19 outcome. These data suggest that depletion of lymphocytes, particularly cytotoxic T lymphocytes that function by eliminating infected cells, coupled with neutrophils capable of mediating a proinflammatory “cytokine storm” may be key players in COVID-19 pathogenesis. While “cytokine storms” have long been associated with acute respiratory distress syndrome (ARDS) caused by SARS coronavirus (SARS-CoV) and MERS coronavirus (MERS-CoV) [2], pro-inflammatory cytokine dynamics in the context of cellular immune responses in COVID-19 have not been well-characterized. This study clearly demonstrates that severe COVID-19 is associated with significant increases in pro-inflammatory cytokines such as IL-6 as well as significant reductions in CD8+ T cells. Th1 antiviral responses appear to be suppressed, which is supported by increases in the Th2 cytokine IL-10. A recent study in 21 patients also demonstrated that COVID-19 induced increases in IL-6 and IL-10 with corresponding lymphopenia [3]. These data indicate that cytokine storms may, in concert with suppressed Th1 antiviral adaptive responses, underlie the pathogenesis of severe COVID-19 disease. These findings are valuable for clinicians as it further supports the significant effect SARS-CoV-2 has on the systemic inflammatory response and gives insight on how to identify patients at risk for severe disease. It demonstrates potentially critical roles for IL-2, IL-6, IL-10, and IFN-γ in severe disease, suggesting that the magnitude of the cytokine storm is associated with severity of disease. Mean IL-6 concentrations have been shown to be 2.9 times higher in patients with severe disease and maximal IL-6 highly predictive of respiratory failure [4,5]. These data also suggest that monitoring N8R and NLR over time could be a way to identify patients early on at risk for developing severe disease [6]. Understanding how to identify which patients who present with COVID-19 will go on to develop severe disease is of paramount importance to clinicians. Monitoring N8R and NLR over time may assist frontline clinicians in identifying those at greatest risk for developing severe COVID-19 and prompt them to institute supportive care earlier or initiate transfer to a higher level of care [6]. Appreciating the role of pro-inflammatory cytokines in the pathogenesis of the disease is important as the scientific community develops therapeutics to treat patients. IL-6 inhibitors such as tocilizumab and siltuximab are already being used in the treatment of patients with severe COVID-19 in hopes of suppressing inflammatory responses and have been adopted in the most recent Chinese National Health Commission Novel Coronavirus Pneumonia guidelines [5,7]. Additionally, levels of fibrinogen, d-dimer, C-reactive protein, and ferritin were found to be significantly higher in patients with severe diseases compared to mild patients and are other potential laboratory markers clinicians can monitor over time to assess how individuals are responding [8]. This is consistent with prior reports that higher levels of C-reactive protein, ferritin and d-dimer were associated with severe COVID-19 [3]. This study was limited to 40 COVID-19 patients, thus limiting the applicability to larger populations. Furthermore, five of the severe patients had fungal or bacterial co-infections, which likely confound associations of inflammatory dysfunction with specific features of COVID-19 disease. Although N8R and NLR remained significant predictors of COVID-19 outcome when the patients with fungal infections were removed, larger studies that can account for variables introduced by co-infections are needed. A subset of patients received methylprednisolone, a corticosteroid with known immunomodulatory effects, further complicating interpretations of COVID-19-specific effects on inflammatory cytokine production and immune cell function. To confirm that lymphocyte depletion and increased numbers of neutrophils are associated with cytokine storms and COVID-19 severity, further data from other cohorts of COVID-19 patients must be obtained. Animal models and samples from patients will be crucial tools for studying the interplay between lymphocytes, neutrophils, and other key cellular mediators of host immunity. In particular, detailed functional studies of immune cells infiltrating the lungs are needed to better understand mechanisms of immune-mediated lung injury. This is particularly relevant in immunocompromised patients, such as those with HIV, cancer, organ transplant recipients, or genetic immune deficiencies. Declaration of Competing Interest The authors declare no conflict of interest.

          Related collections

          Most cited references7

          • Record: found
          • Abstract: found
          • Article: not found

          Clinical and immunologic features in severe and moderate Coronavirus Disease 2019

          Journal of Clinical Investigation
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury

            The outbreak of the 2019-nCoV infection began in December 2019 in Wuhan, Hubei province, and rapidly spread to many provinces in China as well as other countries. Here we report the epidemiological, clinical, laboratory, and radiological characteristics, as well as potential biomarkers for predicting disease severity in 2019-nCoV-infected patients in Shenzhen, China. All 12 cases of the 2019-nCoV-infected patients developed pneumonia and half of them developed acute respiratory distress syndrome (ARDS). The most common laboratory abnormalities were hypoalbuminemia, lymphopenia, decreased percentage of lymphocytes (LYM) and neutrophils (NEU), elevated C-reactive protein (CRP) and lactate dehydrogenase (LDH), and decreased CD8 count. The viral load of 2019-nCoV detected from patient respiratory tracts was positively linked to lung disease severity. ALB, LYM, LYM (%), LDH, NEU (%), and CRP were highly correlated to the acute lung injury. Age, viral load, lung injury score, and blood biochemistry indexes, albumin (ALB), CRP, LDH, LYM (%), LYM, and NEU (%), may be predictors of disease severity. Moreover, the Angiotensin II level in the plasma sample from 2019-nCoV infected patients was markedly elevated and linearly associated to viral load and lung injury. Our results suggest a number of potential diagnosis biomarkers and angiotensin receptor blocker (ARB) drugs for potential repurposing treatment of 2019-nCoV infection. Electronic Supplementary Material Supplementary material is available for this article at 10.1007/s11427-020-1643-8 and is accessible for authorized users.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients

              Background The dynamic changes of lymphocyte subsets and cytokines profiles of patients with novel coronavirus disease (COVID-19) and their correlation with the disease severity remain unclear. Methods Peripheral blood samples were longitudinally collected from 40 confirmed COVID-19 patients and examined for lymphocyte subsets by flow cytometry and cytokine profiles by specific immunoassays. Findings Of the 40 COVID-19 patients enrolled, 13 severe cases showed significant and sustained decreases in lymphocyte counts [0·6 (0·6-0·8)] but increases in neutrophil counts [4·7 (3·6-5·8)] than 27 mild cases [1.1 (0·8-1·4); 2·0 (1·5-2·9)]. Further analysis demonstrated significant decreases in the counts of T cells, especially CD8+ T cells, as well as increases in IL-6, IL-10, IL-2 and IFN-γ levels in the peripheral blood in the severe cases compared to those in the mild cases. T cell counts and cytokine levels in severe COVID-19 patients who survived the disease gradually recovered at later time points to levels that were comparable to those of the mild cases. Moreover, the neutrophil-to-lymphocyte ratio (NLR) (AUC=0·93) and neutrophil-to-CD8+ T cell ratio (N8R) (AUC =0·94) were identified as powerful prognostic factors affecting the prognosis for severe COVID-19. Interpretation The degree of lymphopenia and a proinflammatory cytokine storm is higher in severe COVID-19 patients than in mild cases, and is associated with the disease severity. N8R and NLR may serve as a useful prognostic factor for early identification of severe COVID-19 cases. Funding The National Natural Science Foundation of China, the National Science and Technology Major Project, the Health Commission of Hubei Province, Huazhong University of Science and Technology, and the Medical Faculty of the University Hospital Essen, Germany.
                Bookmark

                Author and article information

                Contributors
                Journal
                EBioMedicine
                EBioMedicine
                EBioMedicine
                The Authors. Published by Elsevier B.V.
                2352-3964
                7 May 2020
                May 2020
                7 May 2020
                : 55
                : 102789
                Affiliations
                [a ]Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, United States
                [b ]Center for Innovation in Global Health, Stanford University School of Medicine, United States
                [c ]Center for Infection and Immunity, Columbia Mailman School of Public Health, United States
                Author notes
                [* ]Corresponding author. alr2105@ 123456cumc.columbia.edu
                Article
                S2352-3964(20)30164-X 102789
                10.1016/j.ebiom.2020.102789
                7204696
                32388462
                8b45bfac-db04-4ec9-bb69-56c7e0d8d4a5
                © 2020 The Authors

                Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

                History
                Categories
                Article

                Comments

                Comment on this article